Completed PHASE3 INTERVENTIONAL 3-arm NCT01294644

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Sponsor: Bayer

Conditions Moderate or Severe Submental Fullness

Interventions Deoxycholic acid injection Placebo

Updated 6 times since 2017 Last updated: May 28, 2015 Started: Jan 31, 2011 Primary completion: Feb 29, 2012 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Moderate or Severe Submental Fullness and is currently completed. Bayer leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Kythera Biopharmaceuticals

Data source: Kythera Biopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Besançon, France , Birmingham, United Kingdom , Bochum, Germany , Cardiff, United Kingdom , Dresden, Germany , Erlangen, Germany , Freiburg im Breisgau, Germany , Geel, Belgium , Genk, Belgium and 15 more locations